since 1980, medifast, inc.(nyse: med) has been a brand recommended by 20,000 doctors. developed by a physician, medifast is a clinically proven nutrition and weight loss company based in maryland. we change lives by producing results and helping those succeed. because everyone has different goals and ways of learning, we offer several support programs as you choose health with medifast. we believe that healthier people are happier people. everyone has the right to feel good about themselves. our vision is to create a world where it's easy to take control of your own well-being. we're on a mission to empower people with the right opportunities to enjoy the healthy life they deserve. we see it every day. the ear-to-ear grin. the “holding back the tears” pride. the glow of pure joy when someone reaches their weight-loss goals. their whole life gets better, and so does yours, because you helped them get there. if you’d like to spend every day helping to change people’s lives for the better
Company profile
Ticker
MED
Exchange
Website
CEO
Daniel Chard
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
HEALTHRITE INC
SEC CIK
Corporate docs
Subsidiaries
Corporate Events, Inc. • Jason Enterprises, Inc. • Jason Pharmaceuticals, Inc. • Jason Properties, LLC • OPTAVIA LLC • OPTAVIA Health Consultation (Shanghai) Co., Ltd. • OPTAVIA (Hong Kong) Limited • OPTAVIA (Singapore) PTE. LTD • Seven Crondall Associates, LLC ...
IRS number
133714405
MED stock data
Latest filings (excl ownership)
8-K
Medifast Announces Fourth Quarter and Full Year 2023 Financial Results
20 Feb 24
10-K
2023 FY
Annual report
20 Feb 24
8-K
Other Events
13 Dec 23
10-Q
2023 Q3
Quarterly report
6 Nov 23
8-K
Medifast Announces Third Quarter 2023 Financial Results
6 Nov 23
8-K
Regulation FD Disclosure
27 Sep 23
8-K
Medifast Announces Quarterly Dividend
7 Sep 23
8-K
Medifast Announces Second Quarter 2023 Financial Results
7 Aug 23
10-Q
2023 Q2
Quarterly report
7 Aug 23
8-K
Medifast Announces Quarterly Dividend
15 Jun 23
Transcripts
MED
Earnings call transcript
2023 Q4
20 Feb 24
MED
Earnings call transcript
2023 Q3
6 Nov 23
MED
Earnings call transcript
2023 Q2
7 Aug 23
MED
Earnings call transcript
2023 Q1
1 May 23
MED
Earnings call transcript
2022 Q4
21 Feb 23
MED
Earnings call transcript
2022 Q3
4 Nov 22
MED
Earnings call transcript
2022 Q2
4 Aug 22
MED
Earnings call transcript
2022 Q1
3 May 22
MED
Earnings call transcript
2021 Q4
24 Feb 22
MED
Earnings call transcript
2021 Q3
5 Nov 21
Latest ownership filings
4
James P. Maloney
19 Mar 24
4
Jonathan Barrett MacKenzie
19 Mar 24
4
Daniel R Chard
19 Mar 24
4
James P. Maloney
15 Mar 24
4
Jonathan Barrett MacKenzie
15 Mar 24
4
Daniel R Chard
15 Mar 24
4
SCOTT SCHLACKMAN
12 Mar 24
144
Notice of proposed sale of securities
8 Mar 24
4
Daniel R Chard
16 Feb 24
4
James P. Maloney
16 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 112.75 mm | 112.75 mm | 112.75 mm | 112.75 mm | 112.75 mm | 112.75 mm |
Cash burn (monthly) | 11.55 mm | (no burn) | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 79.48 mm | n/a | n/a | n/a | n/a | n/a |
Cash remaining | 33.27 mm | n/a | n/a | n/a | n/a | n/a |
Runway (months of cash) | 2.9 | n/a | n/a | n/a | n/a | n/a |
Institutional ownership, Q3 2023
86.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 223 |
Opened positions | 36 |
Closed positions | 45 |
Increased positions | 71 |
Reduced positions | 79 |
13F shares | Current |
---|---|
Total value | 695.39 bn |
Total shares | 9.38 mm |
Total puts | 513.20 k |
Total calls | 109.10 k |
Total put/call ratio | 4.7 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 1.68 mm | $125.64 bn |
Vanguard | 1.57 mm | $117.76 bn |
Renaissance Technologies | 754.21 k | $56.50 bn |
STT State Street | 383.11 k | $29.30 bn |
Dimensional Fund Advisors | 325.34 k | $24.35 bn |
Pacer Advisors | 320.98 k | $24.03 bn |
Citadel Advisors | 245.66 k | $18.39 bn |
First Trust Advisors | 237.63 k | $17.79 bn |
Geode Capital Management | 236.09 k | $17.67 bn |
MS Morgan Stanley | 220.87 k | $16.53 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Mar 24 | Jonathan Barrett MacKenzie | Common Stock | Payment of exercise | Dispose F | No | No | 36.61 | 83 | 3.04 k | 3,917 |
15 Mar 24 | Jonathan Barrett MacKenzie | Common Stock | Payment of exercise | Dispose F | No | No | 36.61 | 51 | 1.87 k | 4,000 |
15 Mar 24 | Maloney James P. | Common Stock | Payment of exercise | Dispose F | No | No | 36.61 | 424 | 15.52 k | 19,534 |
15 Mar 24 | Maloney James P. | Common Stock | Payment of exercise | Dispose F | No | No | 36.61 | 119 | 4.36 k | 19,958 |
15 Mar 24 | Maloney James P. | Common Stock | Payment of exercise | Dispose F | No | No | 36.61 | 73 | 2.67 k | 20,077 |
15 Mar 24 | Chard Daniel R | Common Stock | Payment of exercise | Dispose F | No | No | 36.61 | 1,859 | 68.06 k | 99,821 |
15 Mar 24 | Chard Daniel R | Common Stock | Payment of exercise | Dispose F | No | No | 36.61 | 942 | 34.49 k | 101,680 |
15 Mar 24 | Chard Daniel R | Common Stock | Payment of exercise | Dispose F | No | No | 36.61 | 608 | 22.26 k | 102,622 |
13 Mar 24 | Chard Daniel R | Common Stock | Grant | Acquire A | No | No | 0 | 45,087 | 0.00 | 103,230 |
13 Mar 24 | Maloney James P. | Common Stock | Grant | Acquire A | No | No | 0 | 8,718 | 0.00 | 20,150 |
News
Navigating Challenges and Investor Rewards: Nu Skin Enterprises Ensures Steady Distribution amidst Changing Profits
6 Mar 24
Why International Flavors & Fragrances Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
21 Feb 24
DA Davidson Maintains Neutral on Medifast, Lowers Price Target to $40
21 Feb 24
Palo Alto Networks Issues Weak Outlook, Joins Teladoc Health, SolarEdge Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
21 Feb 24
A Preview Of Medifast's Earnings
19 Feb 24